RXRX stock news · Recursion Pharmaceuticals, Inc.
Get alerts for RXRX
Follow Recursion Pharmaceuticals, Inc. (RXRX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for RXRXRecursion Pharmaceuticals shared its third-quarter results and named Fred Hassan as the new Board Chair.
NeutralRXRX filed a report announcing Q3 results, but it gives no sales, profit, or study figures. It names Fred Hassan board chair, with no details that change the company outlook.
Recursion shared its third quarter 2026 results, showing progress with drugs REC-4881 and REC-1245.
NeutralRecursion released third-quarter 2026 results and described plans for 2 drug programs, without financial figures or trial outcomes. The update does not change how we read the company.
Recursion Pharmaceuticals, Inc. has signed a big deal for a stock sale to raise about $200 million.
NeutralRecursion plans to raise about $200 million by selling new shares and expects cash to fund work into 2029. Existing owners get a smaller share, so it points both ways.
Check out these 10 stocks where more than 33% of shares are being bet against.
NeutralRecursion Pharmaceuticals had 34.95% of its available shares sold short. The article reports no change to its business, so its outlook is unchanged.
Recursion Pharmaceuticals, Inc. has signed an important agreement with Tempus AI, Inc.
NeutralRecursion struck two deals with Tempus that give cash and lower future fees, but also grant Tempus a license and limit Recursion's data access, leaving the story balanced for now.